1. Home
  2. FULC vs CIGL Comparison

FULC vs CIGL Comparison

Compare FULC & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.59

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

CIGL

Concorde International Group Ltd Class A Ordinary Shares

HOLD

Current Price

$1.99

Market Cap

417.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
FULC
CIGL
Founded
2015
1997
Country
United States
Singapore
Employees
N/A
134
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
467.8M
417.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
FULC
CIGL
Price
$3.59
$1.99
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$16.38
N/A
AVG Volume (30 Days)
2.7M
68.1K
Earning Date
04-27-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$1.40
52 Week High
$15.74
$25.00

Technical Indicators

Market Signals
Indicator
FULC
CIGL
Relative Strength Index (RSI) 27.27 56.54
Support Level $2.83 $1.55
Resistance Level $8.18 $2.28
Average True Range (ATR) 0.33 0.16
MACD -0.28 0.01
Stochastic Oscillator 16.98 69.49

Price Performance

Historical Comparison
FULC
CIGL

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

About CIGL Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.

Share on Social Networks: